ArticleEuropean journal of clinical pharmacology2014
Use of the recommended drug combination for secondary prevention after a first occurrence of acute coronary syndrome in France.
Article in European journal of clinical pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 39 citations in OpenAlex.
- Utilization and discontinuation of secondary prevention pharmacotherapy after myocardial infarction: a nationwide cohort study.European heart journal. Cardiovascular pharmacotherapy · 2026Article
- Epilepsy and the risk of adverse cardiovascular events: A nationwide cohort study.European journal of neurology · 2024Article
- Outcomes in Patients with Acute Myocardial Infarction and Known Sleep Apnea: A Nationwide Analysis.Journal of clinical medicine · 2023Article
- Incidence of clinical atrial fibrillation and related complications using a screening algorithm at a nationwide level.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2023Article
- Generating Practice-Based Evidence in the Use of Guideline-Recommended Combination Therapy for Secondary Prevention of Acute Myocardial Infarction.Pharmacy (Basel, Switzerland) · 2022Article
- Temporal Relationship between Atrial Fibrillation and Heart Failure Development Analysis from a Nationwide Database.Journal of clinical medicine · 2021Article
- Outcomes in patients with acute myocardial infarction and new atrial fibrillation: a nationwide analysis.Clinical research in cardiology : official journal of the German Cardiac Society · 2021Article
- Intervening on fear after acute cardiac events: Rationale and design of the INFORM randomized clinical trial.Health psychology : official journal of the Division of Health Psychology, American Psychological Association · 2020Article
- Plasma Galectin-3 predicts deleterious vascular dysfunction affecting post-myocardial infarction patients: An explanatory study.PloS one · 2020Article
- Coronary Events After Dispensing of Ibuprofen: A Propensity Score-Matched Cohort Study Versus Paracetamol in the French Nationwide Claims Database Sample.Drug safety · 2018Article
- Nonadherence in the Learning Healthcare System: Avoiding a Mountain by Seeing the Bumps.Circulation. Cardiovascular quality and outcomes · 2017Article
- Outcomes in patients after myocardial infarction similar to those of the PEGASUS-TIMI 54 trial: A cohort study in the French national claims database.British journal of clinical pharmacology · 2017Article
- Usage patterns of paracetamol in France.British journal of clinical pharmacology · 2016Article
- Comorbidities and concurrent medications increasing the risk of adverse drug reactions: prevalence in French benzodiazepine users.European journal of clinical pharmacology · 2016Article
- Systematic synergy modeling: understanding drug synergy from a systems biology perspective.BMC systems biology · 2015Article
- Heart failure prognosis and management in over-80-year-old patients: data from a French national observational retrospective cohort.European journal of clinical pharmacology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe recommended pharmacotherapy for secondary prevention of acute coronary syndrome (ACS) is long-term treatment with a combination of four therapeutic classes: beta-blockers, antiplatelet agents (including aspirin), statins or other lipid-lowering agents, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. The aim of this study was to describe use and persistence of the recommended drug combination after the first occurrence of ACS in France.
methodsThis was a database cohort study of patients with first registration for ACS between 2004 and 2007 in a representative sample of the French healthcare insurance database (Echantillon Généraliste de Bénéficiaires, EGB). The drugs of interest were those recommended. Persistence was assessed for patients dispensed three or all four drug classes within 2 months following ACS. Discontinuation was defined by a gap of more than 6 weeks between two dispensations. The follow-up period was 24 months after ACS occurrence.
resultsOf 2,057 patients with incident ACS, 872 (42.4 %) had at least one dispensation of each of the four recommended drug classes, and 684 (33.3 %) had three of the four classes. Persistence to treatment at 24 months was 57.4 % (95 % CI [54.0-60.6]) for patients with four classes, and 55.5 % (95 % CI [51.6-59.1]) with three classes. Discontinuation of initial combination was higher in patients aged ≥ 65 years at ACS occurrence, those with associated ongoing chronic disease, and in those who did not suffer myocardial infarction.
conclusionsPost-ACS secondary prevention in France is not optimal, especially in patients who did not have myocardial infarction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.